Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
Huvudupphovsmän: | Hardman, C, Chen, W, Luo, J, Batty, P, Chen, Y, Nahler, J, Wu, Y, Pavord, I, Erpenbeck, V, Sandham, D, Xue, L, Ogg, G |
---|---|
Materialtyp: | Journal article |
Publicerad: |
Elsevier
2019
|
Liknande verk
Liknande verk
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
av: Chen, W, et al.
Publicerad: (2018) -
Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
av: Xue, L, et al.
Publicerad: (2018) -
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
av: Sandham, D, et al.
Publicerad: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
av: Xue, L, et al.
Publicerad: (2019) -
Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells
av: Luo, J, et al.
Publicerad: (2019)